Claus Hanusch
Overview
Explore the profile of Claus Hanusch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
4582
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fasching P, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39998850
Backgound: The GeparOLA study evaluated paclitaxel(P) plus olaparib(O) in neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer (eBC) with homologous recombination deficiency (HRD). HRD was defined by high...
2.
Conforti F, Nekljudova V, Sala I, Ascari R, Solbach C, Untch M, et al.
J Clin Oncol
. 2025 Jan;
:JCO2401360.
PMID: 39883887
Purpose: To assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free survival (iDFS) in randomized clinical trials (RCTs) for early breast cancer...
3.
Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber K, et al.
Cell Rep Med
. 2024 Nov;
5(11):101825.
PMID: 39566464
Therapy-induced molecular adaptation of triple-negative breast cancer is crucial for immunotherapy response and resistance. We analyze tumor biopsies from three different time points in the randomized neoadjuvant GeparNuevo trial (NCT02685059),...
4.
Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Uwe Blohmer J, et al.
Clin Transl Med
. 2024 Apr;
14(4):e1617.
PMID: 38664548
No abstract available.
5.
Link T, Blohmer J, Schmitt W, Kuhlmann J, Just M, Untch M, et al.
Clin Cancer Res
. 2023 Sep;
29(22):4606-4612.
PMID: 37725572
Purpose: The GeparX study investigated whether denosumab as add-on treatment to nab-paclitaxel-based neoadjuvant chemotherapy (NACT) with two different schedules (125 mg/m² weekly vs. day 1, 8 every 22 days) may...
6.
Huober J, van Mackelenbergh M, Schneeweiss A, Seither F, Blohmer J, Denkert C, et al.
NPJ Breast Cancer
. 2023 Apr;
9(1):23.
PMID: 37029138
This retrospective pooled analysis aims to identify factors predicting relapse despite a pathologic complete response (pCR) in patients with breast cancer (BC). 2066 patients with a pCR from five neoadjuvant...
7.
Braun M, Kriegmair A, Szeterlak N, Andrulat A, Schrodi S, Kriner M, et al.
Breast Care (Basel)
. 2022 Aug;
17(3):288-295.
PMID: 35957951
Introduction: The aim of the present study was to analyze the performance of Oncotype DX® multigene assay (ODX®) in patients with 0-3 lymph nodes in a high-volume community hospital. Methods:...
8.
Schilling J, Kurbacher C, Hanusch C, Busch S, Hollander M, Kreiss-Sender J, et al.
Breast Care (Basel)
. 2022 Jun;
17(2):130-136.
PMID: 35702496
Introduction: In a prospective non-interventional study involving 2,173 patients, we showed that use of the oral fixed combination of netupitant 300 mg and palonosetron 0.5 mg (NEPA) for prevention of...
9.
Blohmer J, Link T, Reinisch M, Just M, Untch M, Stotzer O, et al.
JAMA Oncol
. 2022 May;
8(7):1010-1018.
PMID: 35588050
Importance: Adjuvant denosumab might improve disease-free survival in hormone receptor (HR)-positive primary breast cancer (BC). The optimal neoadjuvant nab-paclitaxel schedule in terms of efficacy and safety is unclear. Objective: To...
10.
Gerber B, Schneeweiss A, Mobus V, Golatta M, Tesch H, Krug D, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35158789
Background: The conversion of initially histologically confirmed axillary lymph node-positive (pN+) to ypN0 after neoadjuvant systemic treatment (NAST) is an important prognostic factor in breast cancer (BC) patients and may...